<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2709179/" ref="ordinalpos=4770&amp;ncbi_uid=1994474&amp;link_uid=PMC2709179" image-link="/pmc/articles/PMC2709179/figure/F6/" class="imagepopup">Fig. 6. From: Enhanced Interferon <span class="highlight" style="background-color:">Signaling</span> <span class="highlight" style="background-color:">Pathway</span> in Oral Cancer Revealed by Quantitative Proteome Analysis of Microdissected Specimens  Using 16O/18O Labeling and Integrated  Two-dimensional LC-ESI-MALDI Tandem MS. </a></div><br /><div class="p4l_captionBody"><b>MetaCore analysis of altered signaling pathways in OSCC samples.</b> A, the cytoskeleton remodeling-keratin filaments pathway. B, the type I IFN signaling pathway. Bars labeled in red and blue denote up- and down-regulated target proteins, respectively. Numbers on the bar indicate the experiment in which the target was quantified. 1, 16N1/18T1; 2, 16N3/18T3; 3, 16T1/18N1; 4, 16T2/18N2; 5, 16T3/18N3. JNK, c-Jun NH2-terminal kinase; MAPK, mitogen-activated protein kinase; IFNAR, IFN-alpha/beta receptor. Interaction mechanism is marked with a symbol in the hexagon in the middle of the interaction arrow. CF, complex formation; Cm, covalent modifications; Tr, transcription regulation; B, binding; +P, phosphorylation; âˆ’P, dephosphorylation; Tn, transport; CS, complex subunit.</div></div>